Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015